Neuropsychiatric Disorders Treatment Market Analysis

Global Neuropsychiatric Disorders and Treatment Market Overview

Neuropsychiatric Disorders and Treatment Market size was valued at USD 128.5 Billion in 2022. The neuropsychiatric disorders and treatment market industry is projected to grow from USD 131.6 Billion in 2023 to USD 166.3 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.20% during the forecast period (2023 - 2032). Expanding research and development efforts to create novel treatments for these conditions and a robust pipeline of these medications are the market drivers anticipated to increase the demand for pharmaceuticals for neuropsychiatric disorders and treatments.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Neuropsychiatric Disorders and Treatment Market Trends

• The growing obese population is driving the market growth

Drug-related activities are the preferred strategy among elite players. Drug-related actions include requesting permission to introduce neurological medications at various stages of clinical trials, presenting clinical trial results, and obtaining drug approval across multiple countries. In this market, tactics like mergers and acquisitions, partnerships, and collaborations are negligible. Other tactics include winning awards, spreading awareness, participating in activities relevant to neurology, and so on, which are expected to boost the market CAGR.

The global neuropsychiatric disorder and treatment market is primarily driven by the high frequency of mental diseases and depression, growth in unemployment, and rise in depression brought on by personal loss. During the forecast period, demand for neuropsychiatric disorder and treatment products is anticipated to increase due to the introduction of novel treatments in the neuropsychiatric disorder and treatment market, increased investment in research and development by significant pharmaceutical companies, and demand for affordable medications and therapeutic applications.

Numerous factors, such as increasing media coverage, increased public education efforts, and the expanding accessibility of information online, have contributed to the increased awareness of neuropsychiatric illnesses. Another important aspect is promoting these conditions through social media, celebrity campaigning, and advocacy organizations. More people are expected to seek Treatment for neuropsychiatric diseases as knowledge of these disorders rises. This will lead to earlier diagnosis and Treatment, which can enhance the lives of individuals with neuropsychiatric disorders.

The second leading cause of death worldwide is brain illnesses, which seriously threaten global health. Annual mortality from neurological and neuropsychiatric diseases totals 9 million and 8 million, respectively. Given that this represents almost 30% of fatalities, every third individual on earth will likely experience a family member passing away from a brain illness.  This comes at a heavy cost to societies all around the world. The Worldwide Burden of Disease Study calculates disability-adjusted life-years (DALYs) for the global population with brain illnesses by adding years lost and years lived with disability. The annual DALY count for neurological diseases is 276 million years; for neuropsychiatric conditions, it is 184 million years, totaling 460 million years. This is the main contributor to disability globally as a whole. Thus, such factors are boosting the neuropsychiatric disorders and treatment market revenue.

Neuropsychiatric Disorders and Treatment Market Segment Insights

Neuropsychiatric Disorders and Treatment Disorders Insights

The Neuropsychiatric Disorders and Treatment Market segmentation, based on Disorders, includes degenerative diseases, neurotic disorders, psychosis, and others. Psychosis is the category with the fastest growth. This is because psychosis is a severe mental illness that impacts a person's thoughts, feelings, and actions. The symptoms of psychosis include hallucinations, delusions, and disorganized thoughts. People with psychosis may find it difficult to carry out daily tasks due to these symptoms. Treatments for psychosis are evolving and becoming more effective. In addition, people are becoming more aware of psychosis and the value of early detection and Treatment.

Neuropsychiatric Disorders and Treatment Treatment Insights

The Neuropsychiatric Disorders and Treatment Market segmentation, based on Treatment, includes Shock Treatment, Drug Treatment, and Others. Drug treatment is the industry sector with the fastest growth. This is because pharmacological therapy is the most popular and efficient Treatment for neuropsychiatric illnesses. The availability of new and improved medications is also fueling the expansion of this market segment. New drugs are being created that are less likely to have side effects than older medications and are more effective at managing neuropsychiatric illnesses. People with neuropsychiatric diseases can live more normal, productive lives.

Figure 1: Neuropsychiatric Disorders and Treatment Market, by Treatment, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Neuropsychiatric Disorders and Treatment End User Insights

Based on End Users, the Neuropsychiatric Disorders and Treatment Market segmentation includes Hospitals, Clinics, Research Centre, and Others. The category with the fastest growth is healthcare. This is so because hospitals are where most patients with neuropsychiatric illnesses receive their primary medical care. Hospitals are the fastest-growing market category for neuropsychiatric diseases and treatments for several reasons. Neuropsychiatric disorders are becoming more common. Another development is a rising understanding of the significance of early identification and Treatment of neuropsychiatric diseases.

Neuropsychiatric Disorders and Treatment Regional Insights

The report provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World by region. Due to the significant demand for treatment items from the U.S., North America is predicted to dominate the global market for neuropsychiatric disorders and treatments. The region's dominance results from an increase in U.S. patients who have been given a neuropsychiatric illness diagnosis. The availability of therapeutic facilities like hospitals, clinics, and research facilities further supports the industry.

Further, the major countries studied in the market report are The US, Canada, German, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: NEUROPSYCHIATRIC DISORDERS AND TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe’s neuropsychiatric disorders and treatment market is the second-largest market in the world. Although the European market is expanding more slowly than the North American industry, it is nevertheless anticipated to grow rapidly over the next few years.  The rising incidence of neuropsychiatric conditions like dementia and Alzheimer's disease throughout the continent drives the market there. Further, the German neuropsychiatric disorders and treatment market held the largest market share, and the U.K. neuropsychiatric disorders and treatment market was the fastest-growing market in the European region.

The Asia-Pacific neuropsychiatric disorders and treatment Market is probable to grow at a profligate CAGR from 2023 to 2032. Due to a rapid increase in the consumption of medications to prevent escalating disability and death and improve quality of life, the Asia Pacific region is considered the most desirable for the neurological illnesses treatment market. Moreover, China’s neuropsychiatric disorders and treatment market held the largest market share, and the Indian neuropsychiatric disorders and treatment market is estimated to be the fastest-growing market in the Asia-Pacific region.

Neuropsychiatric Disorders and Treatment Key Market Players & Competitive Insights

Numerous market participants contribute to the market's intense competition. Leading market players regularly invest in creating new medications and therapies and significantly emphasize research and development (R&D). Market participants are undertaking market developments, including periodically investing in developing new drugs and medicines and significantly emphasizing research and development (R&D). They purchase smaller businesses with innovative technologies to grow the neuropsychiatric disorders and treatment industry.

The market is expanding due to the quickening rate at which new treatments and medications are being created in the global neuropsychiatric disorders and treatment industry. In recent years, companies in the neuropsychiatric disorders and treatment industry have frequently concentrated on creating specialized products or treatments. One firm that makes video games for the Treatment of attention deficit hyperactivity disorder (ADHD) is Akili Interactive Labs. These games illustrate how digital health solutions are used further to diagnose neuropsychiatric illness, Treatment, and monitoring. Major players in the neuropsychiatric disorders and treatment market, including AstraZeneca (U.K.), GlaxoSmithKline (U.K.), Universal Health Services Inc. (U.S.), Biogen (U.S.), Boehringer Ingelheim GmbH (Germany), Eli Lilly (U.S.), Bristol-Meyer Squibb (U.S.), Johnson & Johnson (U.S.), Pfizer (U.S.), Wyeth (U.S.), Otsuka Holdings Co. Ltd (Japan), Astellas Pharma Inc. (Japan).

Global biopharmaceutical business AstraZeneca focuses on creating novel medications that meet unmet medical needs. With a portfolio of drugs that treat various illnesses, such as depression, schizophrenia, anxiety, and Alzheimer's disease, the firm has a significant position in the NPT market. Sertraline, a selective serotonin reuptake inhibitor (SSRI) used to treat major depressive disorder (MDD), is the industry leader from AstraZeneca. The business also works on additional depression medicines, such as a novel Sertraline injectable long-acting formulation and an innovative oral treatment dubbed AZD5002.

Boehringer Ingelheim GmbH is a pharmaceutical business focused on research that discovers, develops, produces, and markets cutting-edge pharmaceuticals in human healthcare. With a portfolio of medications that treat various illnesses, such as depression, anxiety, and Alzheimer's disease, the firm has a significant position in the NPT market. Buspar (buspirone), a serotonin 1A receptor agonist used to treat generalized anxiety disorder (GAD), is the firm's product. The business is also working on a variety of additional anxiety-related medications, such as a novel long-acting injectable Buspar formulation and a brand-new oral treatment called BI 109357. The corporation operates in over 130 countries, giving it a worldwide presence. Additionally, it has a proven track record of innovation and is dedicated to funding R&D.

Key Companies in the Neuropsychiatric Disorders and Treatment market include

• AstraZeneca (U.K.)


• GlaxoSmithKline (U.K.)


• Universal Health Services Inc. (U.S.)


• Biogen (U.S.)


• Boehringer Ingelheim GmbH (Germany)


• Eli Lilly (U.S.)


• Bristol-Meyer Squibb (U.S.)


• Johnson & Johnson (U.S.)


• Pfizer (U.S.)


• Wyeth (U.S.)


• Otsuka Holdings Co. Ltd (Japan)


• Astellas Pharma Inc. (Japan)

Neuropsychiatric Disorders and Treatment Industry Developments

September 2021: A collaboration and license agreement for four psychiatric and neurology drugs, including ulotaront (SEP-363856), SEP-378614, SEP-4199, and SEP-380135, were announced by Sumitomo Dainippon Pharma and Otsuka. As per the agreement, Sunovion and Otsuka will equally split the expenses and income from clinical studies, regulatory filings, and marketing in these countries and regions. After further Sumitomo Dainippon Pharma Group and Otsuka talks, additional ulotaront indications and indications for SEP-378614 and SEP-380135 will be discovered.

November 2021: the FDA approved the drug lumateperone for managing the adverse effects of schizophrenia. It is an oral, atypical antipsychotic medication.

December 2022: Inbrija (capivalol) was given FDA approval by Neurocrine Biosciences. It is a breath-activated capsule that releases a single dose of the menopausal-related medicine capivalol to treat bouts of moderate to severe hot flashes.

Neuropsychiatric Disorders and Treatment Market Segmentation

Neuropsychiatric Disorders and Treatment Disorders Outlook

• Degenerative Diseases


• Neurotic Disorders


• Psychosis


• Others

Neuropsychiatric Disorders and Treatment Treatment Outlook

• Shock Treatment


• Drug Treatment


• Others

Neuropsychiatric Disorders and Treatment End User Outlook

• Hospitals


• Clinics


• Research Centre’s


• Others

Neuropsychiatric Disorders and Treatment Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America